phs000280.v5.p1 Atherosclerosis Risk in Communities (ARIC) Cohort | Versions 1-5: passed embargo
| VDAS | 15678 | Longitudinal, Cohort | | |
phs000007.v30.p11 Framingham Cohort | Versions 1-30: passed embargo
| VDAS | 15154 | Longitudinal | | HuGeneFocused50K_Affy Mapping250K_Nsp Mapping250K_Sty Mapping50K_Hind240 Mapping50K_Xba240
|
phs000090.v4.p1 GENEVA: The Atherosclerosis Risk in Communities (ARIC) Study | Versions 1-4: passed embargo
| VDAS | 12771 | Case-Control | | AFFY_6.0
|
phs000209.v13.p3 Multi-Ethnic Study of Atherosclerosis (MESA) Cohort | Versions 1-13: passed embargo
| VDAS | 8296 | Longitudinal, Family | Links | |
phs000086.v3.p1 DCCT-EDIC Clinical Trial and Follow-up of Persons with Type 1 Diabetes | Versions 1-3: passed embargo
| VDAS | 1497 | Clinical Trial, Longitudinal | Links | HumanHap550v3.0 ILLUMINA_Human_1M
|
phs000200.v12.p3 Women's Health Initiative | Versions 1-11: passed embargo Version 12:
| VDAS | 143213 | Partial Factorial Randomized, Double-Blind, Placebo-Controlled, Cohort, Longitudinal | Links | |
phs000343.v3.p1 The Genomics and Randomized Trials Network (GARNET) Vitamin Intervention Stroke Prevention (VISP) trial | Versions 1-3: passed embargo
| VDAS | 2164 | Multicenter, Randomized, Clinical Trial, Double-Blind, Controlled Trial | | HumanOmni1-Quad_v1-0_B
|
phs000363.v17.p11 NHLBI Framingham SABRe CVD | Versions 1-17: passed embargo
| VDAS | 7558 | Cohort | | GeneChip Human Exon 1.0 ST Array Custom Panel TaqMan 350 MicroRNA Custom Panels
|
phs000577.v1.p1 UCDC Longitudinal Study | Version 1: passed embargo
| VDAS | 542 | Longitudinal | Links | |
phs000001.v3.p1 NEI Age-Related Eye Disease Study (AREDS) | Versions 1-3: passed embargo
| VDAS | 4757 | Case-Control | Links | ILMN_Human-1 Mapping50K_Hind240 Mapping50K_Xba240
|
phs000309.v3.p2 The CARDIA-GENEVA Study | Versions 1-3: passed embargo
| VDAS | 1926 | Longitudinal | Links | AFFY_6.0
|
phs000594.v1.p1 A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia | Version 1: passed embargo
| VDAS | 9 | Interventional, Clinical Trial | Links | |
phs000592.v1.p1 Screening Protocol and Longitudinal Study of Bone Marrow Failure Syndromes and Cytopenias | Version 1: passed embargo
| VDAS | 341 | Longitudinal, Prospective | Links | |
phs000236.v2.p2 PAGE: CALiCo: Coronary Artery Risk Development in Young Adults(CARDIA) | Versions 1-2: passed embargo
| VDAS | 3595 | Longitudinal | Links | TaqMan OpenArrays: CALiCo ABD TaqMan Y1 TaqMan OpenArrays: CALiCo ABD TaqMan Y2 TaqMan OpenArrays: CALiCo AOD TaqMan Y1 TaqMan OpenArrays: CALiCo AOD TaqMan Y2 TaqMan OpenArrays: CALiCo DME TaqMan Y1 TaqMan OpenArrays: CALiCo DME TaqMan Y2 TaqMan OpenArrays: CALiCo Sequenom Y2 iSelect Custom Panel
|
phs000018.v2.p1 Search for Susceptibility Genes for Diabetic Nephropathy in Type 1 Diabetes (GoKinD study participants), GAIN | Versions 1-2: passed embargo
| VDAS | 1972 | Case-Control | Links | Mapping250K_Nsp Mapping250K_Sty
|
phs000088.v1.p1 Search for Susceptibility Genes for Diabetic Nephropathy in Type 1 Diabetes (GoKinD study participants and parents), NIDDK | Version 1: passed embargo
| VDAS | 1206 | Case-Control | Links | Mapping250K_Nsp Mapping250K_Sty
|
phs001073.v1.p1 Epigenetic Analysis of Malnutrition | Version 1: passed embargo
| VDAS | 59 | Interventional, Randomized, Clinical Trial | | TruSeq ChIP
|
phs000378.v1.p1 Indianapolis-Ibadan, Nigeria Comparative Epidemiological Study of Dementia | Version 1: passed embargo
| VDAS | 1251 | Community, Longitudinal, Cross-Sectional | Links | HumanOmni2.5
|
phs000605.v1.p1 Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus Trial (The MILES Trial) | Version 1: passed embargo
| VDAS | 111 | Clinical Trial, Clinical Diagnostic Testing, Randomized Controlled Clinical Trial | Links | |
phs000888.v1.p1 eMERGE Network Imputed GWAS for 41 phenotypes | Version 1: passed embargo
| VDAS | 55029 | Case-Control, Cohort | Links | 1000 Genomes
|